The prevalence, intensity, safety, and efficacy of oral anticoagulation (OAC) in addition to dual antiplatelet therapy (DAPT) in "real world" atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) have not yet been fully evaluated. In the CREDO-Kyoto registry cohort-2, 1057 AF patients (8.3%) were identified among 12716 patients undergoing first PCI. Cumulative 5-year incidence of stroke was higher in AF patients than in no-AF patients (12.8% versus 5.8%, P<0.0001). Although the majority of AF patients had CHADS 2 score ≥2 (75.2%), only 506 patients (47.9%) received OAC with warfarin at hospital discharge. Cumulative 5-year incidence of stroke in the OAC group was not different from that in the no-OAC group (13.8% versus 11.8%, P=0.49). Time in therapeutic range (TTR) was only 52.6% with an international normalized ratio (INR) of 1.6-2.6 and only 154 (37.7%) out of 409 patients with INR data had TTR ≥65%. Cumulative 5-year incidence of stroke in patients with TTR ≥65% was markedly lower than that in patients with TTR <65% (6.9% versus 15.1%, P=0.01). In a 4-month landmark analysis in the OAC group, there was a trend for higher cumulative incidences of stroke and major bleeding in the on-DAPT (N=286) than in the off-DAPT (N=173) groups (15.1% versus 6.7%, P=0.052 and 14.7% versus 8.7%, P=0.10, respectively). In conclusion, OAC was underused and its intensity was mostly suboptimal in "real world" AF patients undergoing PCI, which lead to inadequate stroke prevention.
Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Introduction
It has been reported that 5-10% of patients undergoing percutaneous coronary intervention (PCI) have concomitant atrial fibrillation (AF). 1 Most of those patients have an indication for oral anticoagulation (OAC) to prevent stroke or systemic thromboembolism, and also for antiplatelet therapy (APT) to prevent ischemic cardiac events, particularly stent thrombosis (ST).
Drug-eluting stents (DES) has become widely used, and dual APT (DAPT) with aspirin plus thienopyridine for 12 months or more is recommended after DES implantation. 1 Thus, AF patients undergoing PCI often have an indication for long-term use of OAC plus DAPT, though a great concern of bleeding complications has been raised for such a "triple" antithrombotic therapy. [2] [3] [4] [5] [6] [7] However, the prevalence and intensity as well as the safety and efficacy of OAC in combination with DAPT in "real world" AF patients undergoing PCI have not yet been fully evaluated. For patients receiving triple therapy in the real world clinical practice, OAC could be less intensive due to a concern on bleeding complications. It is unknown, however, whether the less intensive OAC in patients receiving concomitant DAPT is effective in preventing stroke. Also unknown is the effect of DAPT on long-term cardiovascular outcomes in patients receiving concomitant OAC. Consequently, we investigated the practice pattern and outcome regarding OAC-and DAPT-use among AF patients in a large observational PCI database in Japan with 4-7 years of follow-up.
Methods
The CREDO-Kyoto (Coronary REvascularization Demonstrating Outcome Study in Kyoto) Registry Cohort-2 is a physician-initiated, non-company-sponsored, multicenter registry enrolling consecutive patients undergoing first coronary A total of 15939 patients undergoing first coronary revascularization were enrolled in the registry. We excluded 99 patients who refused study participation, 2782 who underwent coronary artery bypass grafting, and 342 who died during the index hospitalization. Thus, the current study population consisted of 12716 patients undergoing first PCI who were alive at hospital discharge. (Figure 1 ).
Recommended antiplatelet regimen for PCI-stenting was aspirin (≥81mg daily) indefinitely and thienopyridine (200 mg 4 ticlopidine or 75 mg clopidogrel daily) for at least 3 months. Choices regarding duration of DAPT and administration of warfarin in AF patients were left to the discretion of each attending physician. Persistent discontinuation of the antithrombotic drugs was defined as withdrawal lasting for at least 2 months. Withdrawal of DAPT was defined as persistent discontinuation of either aspirin or thienopyridine.
We defined AF patients as those with a preexisting diagnosis of AF and those who developed new onset AF during their index hospitalization. The primary outcome measure was stroke including both ischemic and hemorrhagic strokes. Stroke was defined as an acute onset of a focal neurologic deficit of presumed vascular origin requiring hospitalization with symptoms lasting >24 hours or resulting in death. The types of strokes were distinguished by imaging studies to be either hemorrhagic or ischemic.
Cerebral bleeding that occurred secondary to ischemic stroke was not regarded as hemorrhagic stroke. We used the Cox proportional hazard model to adjust for the differences in baseline patient characteristics, procedural factors, medications, and center. The unadjusted and adjusted risk for clinical event was expressed as a hazard ratio (HR) with its 95%
confidence interval (CI). The detailed methods of the multivariable analyses are described in Supplementary Methods.
The landmark analysis based on DAPT-use at 4-month after the index PCI was conducted as described previously. 12 Eligible patients for the landmark analysis were those who were alive and free from stroke, MI, ST and major bleeding at the 4-month landmark point. Taking a 1-month window period, the 4-month landmark point was selected because DAPT for at least 3-month had been recommended after implantation of sirolimus-eluting stent, which was the most commonly used DES in this study population.
All analyses were conducted by two physicians (Goto K and Nakai K) and a statistician (Morimoto T) with the use of SAS 9.2 and JMP 7.0 (SAS Institute Inc, Cary, NC). All the statistical analyses were 2-tailed, and probability values <0.05 were considered statistically significant.
Results
Among the entire 12716 study patients, 1057 patients (8.3%) had AF. Baseline characteristics of the entire study population comparing AF and no-AF patients are shown in Supplementary Table 1 . During the median follow up of 5.1 (Q1-Q3: 4.3-5.9)
years, a total of 2065 patients died and 800 patients had strokes. Cumulative 5-year incidence of stroke was significantly higher in AF patients than in no-AF patients (12.8% and 5.8%, P<0.0001) ( Figure 2A ). After adjusting confounders, the excess risk of AF patients relative to no-AF patients for stroke remained significant (Table 2) .
Among 1057 AF patients, although a large number of patients had a CHADS 2 score ≥2, only 506 patients (47.9%) received OAC with warfarin (Table 1) .
Patients receiving OAC at hospital discharge as compared with no-OAC patients had higher prevalence of persistent or permanent AF, although the distributions of the CHADS 2 score were similar between the 2 groups (Table 1 and Supplementary   Figure 1 ). The vast majority of OAC patients received concomitant DAPT, even though DAPT was less prevalent in OAC 6 patients than in no-OAC patients.
After 5 years, OAC was discontinued in 22.7% of patients in the OAC group, while OAC was started in 31.6% of patients in the no-OAC group (Supplementary Figure 2) . Cumulative 5-year incidence of stroke was high and not significantly different between the OAC and no-OAC groups (13.8% and 11.8%, P = 0.49) ( Figure 2B ). Even after adjustment of baseline differences, the effect of OAC for stroke remained insignificant. Cumulative incidence of major bleeding also showed no difference between the OAC and no-OAC groups. Cumulative incidence of MI as well as ST was significantly lower in the OAC group than in the no-OAC group (Table 2) . Baseline characteristics including the CHADS 2 score were similar between the 2 groups of patients with TTR ≥65%
(N=154) and TTR <65% (N=255) with the INR range of 1.6 to 2.6 (Supplementary Table 2 ). Cumulative 5-year incidence of stroke was significantly lower in patients with TTR ≥65% than in those with TTR <65% (6.9% and 15.1%, P=0.01) ( Figure 2C ).
After adjusting confounders, TTR ≥65% remained to be significantly associated with lower risk of stroke (Table 2) . Among 68 patients in the OAC group who had stroke during follow up, INR data within 30 days before or at the time of the stroke were available in 27 patients. Ischemic stroke occurred mostly in patients with latest INR values of <1.6 ( Figure 3C ).
During follow-up, DAPT was maintained more frequently in the OAC group than in the no-OAC group (Supplementary Figure 3) . At 4-month, DAPT was maintained in 286 (62.3%) out of 459 OAC patients eligible for the landmark analysis. The on-DAPT patients at 4-month more often had multivessel coronary artery disease and DES-use as compared with the off-DAPT patients (Supplementary Table 3 ). The average TTR was significantly lower in on-DAPT than in off-DAPT patients (49.2% versus 59.1%, P=0.002). Cumulative incidences of stroke and major bleeding including hemorrhagic stroke tended to be higher in on-DAPT than in off-DAPT patients (Figure 4 ). There were no differences in the cumulative incidences of MI and ST regardless of DAPT use at 4-month (Supplementary Table 4 ).
Discussion
The main findings of the present study were as follows: (1) In "real world" AF patients undergoing PCI, OAC was underused, and its intensity was mostly suboptimal; (2) OAC at hospital discharge was not associated with lower stroke incidence presumably due to its low intensity overall; (3) Optimal as compared to suboptimal OAC was associated with markedly lower stroke incidence; (4) Prolonged DAPT in addition to OAC did not reduce stroke risk. Despite three-forth of AF patients having a CHADS 2 score ≥2, OAC was used only in 47.9% of patients in this study, which is consistent with previous reports. Among previous observational studies that included patients undergoing PCI with an indication for OAC, the prevalence of OAC ranged from 9-85% with an average of 51%. 2, 4-7, 13 Thus, in "real world" AF patients undergoing PCI, OAC is underused presumably due to physicians' concern for bleeding complications. Most previous studies, indeed, showed high hemorrhagic risk for triple therapy, 2-7 up to 6 times higher than no-triple therapy. 2 OAC with dose-adjusted warfarin as compared to either placebo, aspirin, or DAPT was associated with marked risk reduction for stroke in randomized controlled trials. 14,15 Furthermore, several previous observational studies in the PCI setting also showed better cardiovascular outcomes, despite excess in bleeding events, in patients receiving OAC than in patients not receiving 8 OAC. [4] [5] [6] [7] 16 In the present study, however, OAC at hospital discharge was not associated with lower risk for stroke. The main reason for the lack of efficacy for OAC in preventing stroke could be the low intensity of OAC observed in the present study.
Only 37.7% of patients had TTR ≥65% even when the therapeutic INR range was set at lower range of 1.6 to 2.6. Patients with TTR ≥65% actually had a markedly lower risk for stroke than patients with TTR <65%.
There is insufficient data regarding the intensity of OAC in AF patients undergoing PCI. 4 Presumably due to the prospective design, the INR control in these two studies was excellent. However, in "real world" AF patients undergoing PCI, OAC may be less intensive than that observed in prospective studies or randomized controlled trials. In the non-PCI AF population, TTR in the retrospective studies range from 29-75% with an average of 53% in contrast to that in the randomized controlled trials, ranging from 44-73% with an average of 67%. 17 In the real world PCI population with mandatory DAPT at hospital discharge, the intensity of OAC could be further shifting to lower INR control due to physicians' concern for bleeding complications, as shown in our study. Conversely, however, the current study strongly suggests that the optimization of OAC would be crucial for stroke prevention in AF patients undergoing PCI.
In the present study, DAPT was maintained beyond 4-month in a significant proportion of AF patients with OAC. In the 4-month landmark analysis, OAC was less intensive in on-DAPT than in off-DAPT patients, leading to a trend toward higher incidence of stroke in on-DAPT patients. Also, on-DAPT patients tended to have higher risk of major bleeding compared with off-DAPT patients. Furthermore, there was no difference in the risk of MI or ST between the two groups. Recent several randomized controlled trials and observational studies enrolling patients mostly without AF suggested that prolonged DAPT after PCI, compared to short-term, did not demonstrate better cardiovascular outcomes including ST, but was associated with excess bleeding events. [18] [19] [20] Considering the increased risk of major bleeding in the setting of triple therapy, duration of DAPT should be as short as possible. To reduce stroke risk, we should focus more on optimizing OAC rather than prolonging DAPT. The What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST) study demonstrated that triple therapy (OAC plus DAPT) as compared with double therapy (OAC plus clopidogrel) was associated with significantly higher rates of bleeding events without any improvement of cardiovascular outcomes. 21 Double therapy with OAC plus a thienopyridine may be an attractive alternative to triple therapy. The recent report by Lamberts et al. also supports this therapeutic concept. 6 There are several important limitations in this study. First, due to the observational study design, we could not deny the influence of selection bias and unmeasured confounders regarding the effect of OAC on stroke reduction. Second, stroke was not adjudicated by neurologists in routine. Third, we did not have INR data for all patients with OAC, and the number and interval of INR measurements varied widely among patients. Forth, there was substantial cross-over between the OAC and no-OAC groups during follow-up, although the degree of cross-over was relatively low as compared to recent OAC studies. 15, 22 Fifth, there may be some difference in the intensity of OAC for AF patients in a real clinical practice between Asian and Western countries.
Asians have been reported to be associated with 4 times higher risk of intracranial hemorrhage than Caucasians under OAC with warfarin. 23 Also, Japanese elderly patients are known to have high risk of major bleeding at the INR level of >2.6, 24,25 which lead to the recommendation of low intensity INR control (1.6-2.6) for elderly patients in the Japanese guidelines. 11 Indeed, Asian physicians prefer low intensity INR control regardless of patient's age even in the setting of randomized controlled trials. 26, 27 Finally, TTR cut-off level of 65% according to the INR range of 1.6-2.6 was not pre-specified. However, the results were consistent even when the TTR cut-off level was set at either 60% or 70% (Supplementary Figure 4) .
Disclosures
None of the authors have potential conflicts of interest.
Figure legends
Figure 1
Study flow chart.
CABG=coronary artery bypass grafting, M=months.
Figure 2
Cumulative incidence of stroke comparing (A) AF versus no-AF patients, (B) OAC versus no-OAC at hospital discharge in AF patients, and (C) TTR≥65% versus TTR<65% in the OAC patients. 
Figure 4
Cumulative incidence of (A) stroke and (B) major bleeding in the OAC patients based on DAPT use at the 4-month landmark point. * The sum of the numbers of ischemic (or unspecified) and hemorrhagic stroke events is not necessarily equal to the number of overall stroke events because of patients with multiple events. † Only 8 out of 800 strokes (1.0%) were unspecified because of lack of imaging information, all of which were in no-AF patients. ‡Academic Research Consortium definite. ** Not available because of small number of events. 
